glp-1 kidney disease Potential kidney-protective and other effects of receptor GLP-1RA in Different HFpEF Phenotypes

Description

[DOI] [PubMed] [Google Scholar] 418.Moon M.J., Kim H.Y., Kim S.G., Park J., Choi D.S., Hwang J.I

Normally: Angiotensin I (ACE) Angiotensin II Angiotensin II causes: Vasoconstriction Aldosterone release Increased blood pressure After Captopril: Angiotensin II Vasoconstriction Aldosterone Blood pressure Bradykinin (causes cough) Indications Hypertension Heart failure Post-myocardial infarction Diabetic nephropathy Left ventricular dysfunction Dosage Hypertension: Start: 12.525 mg 23 times daily Maintenance: 2550 mg 23 times daily Heart Failure: Start low (6.25 mg TDS) Titrate gradually Dose adjustment needed in renal impairment

Lifestyle changes and metformin are standard treatments if you have PMOS, but early research suggests semaglutide may also help improve insulin sensitivity in people with Type 2 diabetes

406: On the Appropriate Use of GLP-1 Receptor Agonists and GIP/GLP-1 Receptor Agonists" PMDA, "Notice Regarding the Appropriate Use of GLP-1 Receptor Agonists and GIP/GLP-1 Receptor Agonists (April 2025)" The Japan Diabetes Society, "Position Statement on the Off-Label Use of GLP-1 Receptor Agonists and GIP/GLP-1 Receptor Agonists" Mounjaro (Tirzepatide) Pharmaceutical Interview Form (Revised May 2026, 5th Edition) Written by: Tigrey (Graduate student in life sciences, Web writer) This article is intended for general information purposes only and does not recommend medical diagnosis or treatment.